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The incidence of tuberculosis (TB) is three
times higher inside correctional settings than
outside, making mastery of TB treatment
guidelines a "must" for correctional HIV pro-
fessionals. Updated guidelines highlighting
new regimens and clinical practices for the
treatment of tuberculosis (TB) and human
immunodeficiency virus (HIV) co-infected indi-
viduals were just published (CDC, 1998). The
guidelines re- emphasize previously well-rec-
ognized principles of TB treatment, and
extend these concepts to TB in the context of
HIV co-infection. The following article will
review these recent developments and pro-
vide insight into the complex issues surround-
ing the care of TB and HIV infected individuals
in the correctional setting.
• Effect of TB/HIV Co-Infection 
Initial studies of TB and HIV concentrated on
the impact of HIV on the natural progression
of TB. HIV infected individuals appear to be
more likely to be infected with TB if exposed,
compared to non-HIV infected individuals.
Once infected, the natural history of TB pro-
gression from infection to disease and death
may be telescoped into a matter of weeks in
the HIV infected individual. 
More recent studies have revealed that the
impact of TB on the progression of HIV may be
just as devastating. The host immune
response to Mycobacterium tuberculosis
(Mtb), the causative agent of TB, appears to
increase HIV replication, both systemically and
locally. In some patients with active TB, plas-
ma HIV RNA levels (viral load) rise substan-
tially before TB is diagnosed and viral loads fall
with TB treatment alone (Havlir, Barnes,
1998). These facts serve therefore to under-
score the absolute importance of prevention,
early recognition and effective treatment of
both TB and HIV in the correctional setting.
• Treatment of TB and HIV
Decisions regarding treatment of active tuber-
culosis are constrained by the choice of HIV
treatment regimen (see Table 1, page 3, for a
detailed summary of treatment regimens for
TB/HIV co-infected patients). Therefore, the
HIV infection status of the patient should be
ascertained prior to initiation of TB prophylax-
is or early in the treatment of active disease.
Two new classes of drugs, the non-nucleoside
reverse transcriptase inhibitors (NNRTI’s) and
protease inhibitors (PI's), are known to interact
with rifampin, one of the drug cornerstones of
TB treatment. Rifampin, a potent inducer of
the cytochrome P450 system, reduces the
levels of PI's and NNRTI's in the plasma;
reduction in plasma levels of these drugs to
less than therapeutic levels may lead to the
development of resistant mutations of the HIV
virus. Furthermore, NNRTI's and PI's may
impair the clearance of rifampin, thereby pre-
disposing the patient to drug side effects. 
One of the new CDC recommendations is to
use rifabutin to replace rifampin in TB treat-
ment regimens when patients are on NNRTI's
and PI's.  Because of the possibility that a
rifabutin-containing regimen may reduce the
long-term efficacy of the TB treatment regi-
men, it is now recommended that a four-drug
regimen, including rifabutin, be used to treat
TB for the first 2 months, even if drug suscep-
tibility is demonstrated.
If the HIV infected patient is already on PI’s or
NNRTI’s, interruption of the HIV treatment reg-
imen is not recommended; modification of the
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Greetings colleagues,
March winds bring hope for Spring, fresh air, and sunshine -- all balms for the human spirit. Once upon a time, not too long ago, fresh air and sunshine
were the only available balms for tuberculosis, the disease then known as consumption. The good news is that treatment of tuberculosis (TB) has come
a long way since patients were bundled in blankets and put out to sun at a sanitarium in the snowy hinterlands of this nation. The bad news is that TB
has not disappeared along with the TB "sans," even though much more effective treatment is now available. TB, like its fellow traveler HIV, is a disease
affecting marginalized populations. Lack of access to TB prevention and treatment is the main reason why TB still ferments among impoverished sub-
populations of Manila, New Delhi, Johannesburg and among the denizens of our jail and prison systems. 
Correctional populations are disproportionately affected by this silent plague. In the early 1990's, the New York correctional system witnessed a resur-
gence of TB of the multi-drug resistant variety (MDR TB) that had a tremendous impact on patients, health care providers and members of  security staff
(see MMWR 1992 Jul 17; 41(28): 507-9). Active intervention by the New York State correctional system in partnership with the Centers for Disease Control
(CDC) and the New York Department of Health brought the epidemic of MDR TB under control. 
Yet TB, like the mythical hydra, is a difficult beast to tame. This past month the CDC published a report on TB outbreaks in two California prisons (MMWR,
1998; 48(04):79-82; http://www.cdc.gov/epo/mmwr/mmwr.html). This report served to document, once again, the many problems associated with the diag-
nosis, treatment,  and prevention of TB among HIV infected patients in the correctional setting. The index case patient at Prison A was HIV infected and
anergic to TB skin testing and control skin tests on entry to the prison setting. Even though the patient had no symptoms, the TB screening protocol at
Prison A called for three procedures to rule out TB: the PPD skin test, a chest x ray and sputum analysis.  These procedures might have been considered
excessive, had the patient not been incarcerated. Skin testing frequently fails to identify TB disease among incarcerated persons (Bellin, 1993) and chest
x rays may fail to demonstrate abnormalities in patients who have both HIV and TB disease (Havlir 1999).
Even though these excellent screening policies were in place, Prison A failed to recognize TB in this patient when it developed later on during his incar-
ceration. The patient was treated for pneumonia with antibiotics before TB was finally diagnosed and he was placed in respiratory isolation. A second
patient, at Prison B, received similar treatment for "pneumonia" before TB was finally diagnosed and he was placed in respiratory isolation. In both cases
the diagnosis of TB was delayed until appropriate sputum specimens were sent.  As a result, 20 contacts converted their TB (PPD) skin test, and nine
additional contacts developed active tuberculosis. 
In both cases, transmission of TB occurred because of a failure to "Think TB," to paraphrase the CDC dictum. In short, any HIV infected patient who has
respiratory symptoms should undergo a chest x ray and screening for TB, regardless of whether prior screenings failed to find TB. A negative chest x ray
does not exclude TB in an HIV infected patient who has other TB symptoms, such as fever and weight loss, and other discernible cause of fever.
I would like to call attention, while we are on the topic of TB, to a paradoxical phenomenon: the worsening of TB or the emergence of TB following the ini-
tiation of antiretroviral therapy in AIDS patients. This subject was reviewed in the American Journal of Critical Care and Respiratory Medicine (Narita M.
et.al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Repir Crit Care Med 1998; 158:157-61.) and I have
seen or heard of at least three patients with clinical courses fitting this description in the past year. The syndrome is characterized by clinical deteriora-
tion, increased adenopathy, development of "miliary" pulmonary infiltrates, effusions, and so on, soon after the initiation of HAART.  The role of steroids
in the treatment of these paradoxical exacerbations of TB symptoms remains to be determined. Be on the look out for this unusual manifestation of TB in
the era of HAART!
TB in the setting of HIV infection is the topic of the lead article in HEPP News this month. The author, Jane Carter M.D., is the Director of the Rhode Island
TB clinic and also participates in the care of TB-infected patients at a Federal correctional facility located in Rhode Island. TB prevention may be facili-
tated by this month's HEPPigram, which addresses helpful criteria for respiratory isolation in corrections. HIV 101 provides information on current treat-
ment dosages and common side effects associated with TB medications. HIV providers reviewing the contents of this issue should be able to describe
TB medications that cannot be used with protease inhibitors, name several possible approaches to treatment of TB in patients with HIV infection and list
protocols for isolation of patients with suspected TB.
Next month we will bring you a full update from the 6th Conference on Retroviruses and Opportunistic Infections in Chicago. In the meantime, please take
the time to write to us and let us know if our content and focus work for you! Thanks for joining us for this special issue on TB.
Sincerely,  
Anne S. De Groot M.D.
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TB treatment to allow for the use of the PIs
and NNRTIs is preferred. However, if the
diagnoses of TB and HIV are made simulta-
neously, the relative risks of simultaneous
initiation of therapy for both diseases versus
the treatment of TB first must be considered
on a case-by-case basis. Three options are
available: (1) TB can be treated alone for at
least 2 months with subsequent modification
of the standard TB regimen (see Table 1);
(2) TB can be treated for 6 months with sub-
sequent initiation of HIV therapy; (3)
Simultaneous HIV and TB treatment may be
initiated with rifabutin, substituting rifampin if
PI’s or NNRTI’s are used for HIV therapy. By
implication, the clinician must assess
whether it is appropriate to delay treatment
of HIV infection in favor of treating TB dis-
ease. Delaying treatment of active TB dis-
ease, in favor of treating HIV first, is not a
clinical option. 
• Nonadherence to TB Treatment
Adherence to TB therapy has been empha-
sized for years as the most important princi-
ple in the treatment of TB disease.
Concomitant treatment of TB and HIV
requires meticulous adherence to both sets
of drugs. The patient must be taught that
each of the drugs has an effect on the other.
For example, if the patient becomes nonad-
herent with the HIV medications, the serum
rifabutin level will fall and may place the
patient at risk for the development of drug
resistant TB. Nonadherence in this scenario
may lead not only to resistant TB, but also to
resistant HIV.  It does, therefore, entail a
double risk. 
• Treatment of Multi-Drug Resistant TB 
Treatment of drug resistant forms of TB in
the setting of HIV is not discussed in-depth
here because it is complex and requires
ndividualization. Identifying MDRTB by
doing appropriate cultures is an important
first step. Correctional HIV providers should
send appropriate clinical specimens from
every suspected or active TB case to com-
petent microbiology laboratories for culture
and sensitivity testing.  Should correctional
providers identify a case of MDRTB, they
should take the opportunity to obtain consul-
tation with their state TB control officers and
to confer with physicians experienced in the
management of drug resistant TB. 
• Directly Observed Therapy 
Directly observed therapy (DOT) is accepted
as the standard mechanism for ensuring
adherence both inside and outside of the
correctional setting and is recommended by
the World Health Organization (WHO). The
use of fixed dose combination pills is an
additional option, which may eliminate the
patient's ability to selectively uncouple drug
regimens. Unfortunately, fixed dose combi-
nations are not available for all drug combi-
nations and no fixed dose combination is
available that includes rifabutin. Because it
is feasible in the correctional setting, DOT
for all TB regimens (including prophylaxis) is
already the standard of care. 
Double Trouble: TB and HIV in the Correctional Setting
continued from page 1
M a r c h  1 9 9 9  •  V o l u m e  2 ,  I s s u e  3 3
Table 1- Treatment Options for fully susceptible TB Disease in the setting of HIV infection.  See
HIV 101 in this newsletter for dosages.
6-month RFB-based therapy (may be prolonged to 9 months)
INDUCTION PHASE CONTINUATION PHASE COMMENTS
Regimen A daily for 8 weeks
or
Regimen A daily for 2 weeks then 2-3 times a
     week for 6 weeks.
Regimen B daily for 18 weeks
or
Regimen B twice a week for 18 weeks
RFB should not
be used with
ritonavir or
delavirdine
9-month SM-based therapy (may be prolonged to 12 months)
INDUCTION PHASE CONTINUATION PHASE COMMENTS
Regimen C daily for 8 weeks
or
Regimen C daily for 2 weeks then 2-3 a week
     for 6 weeks
Regimen D 2-3 times a week for 30 weeks May be used with
PI’s, NNRTI’s or
NRTI’s
6 month RIF-based therapy (may be prolonged to 9 months)
INDUCTION PHASE CONTINUATION PHASE COMMENTS
Regimen E daily for 8 weeks
or
Regimen E daily for 2 weeks then 2-3 times a
     week for 6 weeks
or
Regimen E 3 times a week for 8 weeks
Regimen F daily for 18 weeks
or
Regimen F 2 times a week for 18 weeks
or
Regimen F 3 times a week for 18 weeks
No PI’s or
NNRTI’s may be
used with
Rifampin
INH=isoniazid; RIF=rifampin; PZA=pyrazinamide; EMB=ethambutol; SM=streptomycin; RFB=rifabutin
continued on page 4
Regimen A: INH, RFB, PZA, EMB. 
Regimen B: INH, RFB.
Regimen C: INH, SM, PZA, EMB.
Regimen D:  INH, SM, PZA.  If SM is not used for the recommended 9 months, EMB should be added with prolongation of therapy
to 52 weeks.
Regimen E:  INH, RIF, PZA, EMB or SM.  PZA is continued throughout the induction phase; EMB stopped after susceptibilities
tests demonstrate susceptibility to INH and RIF.
Regimen F:  INH, RIF.
In the correctional setting, all intermittent regimens are carried out under DOT conditions. Prolongation of regimens occurs in
patients with delayed clinical response such as positive sputum cultures after 2 months or progression of signs and symptoms of
TB beyond 2 months.
• Treatment of TB Infection (TB Prophylaxis) 
Obviously it is much easier and safer to treat TB in its latent form than
in its active form. Therefore, screening for TB infection is an impor-
tant part of the annual health care evaluation of the HIV infected indi-
vidual. A PPD (TB skin test) of greater than 5 mm in duration is con-
sidered to be an indication of TB infection in HIV infected individuals:
10 mm is the cutoff for incarcerated patients who are not HIV
seropositive. Clearly, the HIV risk status of the patient should be
assessed and HIV testing should be advised if appropriate, as HIV-
infection status affects the interpretation of the TB skin test.  Careful
clinical history documentation may sometimes reveal a history sug-
gestive of TB exposure, which would hold as much or greater weight
in the decision to initiate therapy for TB infection as would a positive
PPD.  In fact, the most important requirement before initiating thera-
py for latent tuberculosis is a careful history and physical combined
with appropriate radiographic screening to rule out active TB. 
There are three options for the treatment of TB infection in the HIV
infected individual. Note that the following regimens incorporate
some new concepts in TB treatment. All of the following regimens
should be provided via DOT in the correctional setting:
1) 9 months of isoniazid (INH). (270 daily doses over 9 months con-
tinuously or over 12 months, if interruptions occur, vs at least 76
doses of twice weekly doses over 9 months continuously or 12
months with interruptions.)
2) 2 months of rifampin (RIF) and pyrazinamide (PZA) administered
daily.  (60 doses over 2 months continuously or 3 months with inter-
ruptions.) Missed doses and/or intermittent therapy with rifampin and
pyrazinamide, even under DOT conditions, is not an option.
3) 2 months of rifabutin and pyrazinamide administered daily may be
an option for patients on NNRTI's or PI's. This regimen has no clin-
ical trial experience but is based on expert opinion. (Same dose
count as option #2.)
Individuals who complete an adequate course of therapy (whether
for TB infection or TB disease) require no specific follow-up screen-
ing care unless they have symptoms of active TB or are subse-
quently re-exposed to an individual with infectious TB. The problem
here is how to ensure adequacy of therapy whenever DOT is not uti-
lized.
Correctional HIV providers need to take advantage of their DOT
option for these regimens. It is important to develop methods of con-
firming DOT: you may wish to ask the medline staff to keep a sepa-
rate record of DOT treatment for TB, and to notify you if more than
one dose is missed in a given period. Even if medline keeps track of
a patient's adherence to TB medications, you may wish to keep your
own records; a standard calendar can serve as a DOT flow sheet.
While DOT may be facilitated by the correctional environment, conti-
nuity of care of a TB/HIV co-infected patient may be challenged by
transf rs between correctional facilities and treatment in the commu-
nity setting. 
The issues raised in this article serve to underscore the importance
of close communication between service providers should a patient's
TB and HIV regimens be administered by different physicians within
the correctional and community settings.
References: 
1. CDC. Prevention and treatment of Tuberculosis among individuals infected with
Human Immundeficiency Virus: Principles of therapy and revised recommendations.
MMWR 1998: 47 (No. RR-20).
2. Havlir, DV, Barnes, PF. Tuberculosis in patients with Human Immunodeficiency Virus
infection. NEJM, 1998; 340 (5): 367-373.
Drug Daily Dose 2x weekly
dose
3x weekly
dose
Side Effects/Toxicities*
Isoniazid (INH):
PO
5 mg/kg
(300mg)
15 mg/kg
(900mg)
15 mg/kg
(900mg)
-hepatic enzyme elevation
-hepatitis
-peripheral neuropathy
-CNS effects
Rifampin (RIF):
PO or IV
10 mg/kg
(600mg)
10 mg/kg
(600mg)
10 mg/kg
(600 mg)
-orange discoloration of secretions and
urine (occurs in all patients)
-GI upset
-hepatitis
-bleeding problems
-flu-like symptoms
-rash
Pyrazinamide
(PZA): PO
15-25 mg/kg
(2gm)
50-70 mg/kg
(4gm)
50-70 mg/kg
(3gm)
-GI upset
-hepatitis
-hyperuricemia
-arthralgias
-rash
Ethambutol
(EMB): PO
15-25 mg/kg 50 mg/kg 25-30 mg/kg -optic neuritis (decreased red-green
color discrimination, decreased visual
acuity)
Streptomycin
(SM): IM
15 mg/kg
(1 gm)
15 mg/kg
(1 gm)
15 mg/kg
(1 gm)
-Ototoxicity (hearing loss, vestibular
dysfunction)
-renal toxicity
Parenthesis indicate the maximum dosage.
Standard Treatment Guidelines for Tuberculosis Disease
This chart provides a framework for the treatment of patients with TB disease.  It is strongly recommended that TB treatment be under-
taken in consultation with a physician who is experienced with TB management.  Adapted from the National Tuberculosis Center pock-
et card.  For more information, contact the National Tuberculosis Center at the New Jersey Medical School: 
Tel: 973.972.3270. Fax: 973.972.3268.  Website: http://www.umdnj.edu/ntbc. TB Infoline: 1-800-4TB-DOCS
First line therapies are listed; parenthesis indicate the maximum dosage.
*Not all side effects and toxicities are listed.  Check package insert or the Physician's Desk Reference for more complete information.
Note: 
• If primary INH resistance is greater than 4% in the community, all patients should initially be started on a 4-drug regimen (INH, RIF, 
PZA, EMB or SM).
• Never add a single drug to a failing regimen or one that failed in the past.  
• PZA and SM are contraindicated in pregnancy.
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A s k  T h e  E x p e r t
W h a t  W o u l d  Y o u  D o ?
Renee Ridzon, MD
Medical Officer, Surveillance and Epidemiology Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA. 
The patient who is at increased risk of reactivation of Mycobacterium tuberculosis infection because of his infection with HIV is a high pri-
ority candidate for preventive therapy, and an attempt should be made to provide an effective course of therapy to treat his latent infection.
This man's history underscores the need for documentation of the positive tuberculin skin test result and toxicity to isoniazid. There should
be an attempt to obtain medical records from the time of the described episode of nausea, vomiting and jaundice. My work up would cer-
tainly include a look for infectious agents, such as Hepatitis B virus or Hepatitis C virus, which may have contributed to or been responsi-
ble for the patient's symptoms of nausea, vomiting and jaundice. Before preventive therapy is started, I would perform a symptom check
and a chest x ray to confirm that there is no active disease. This is especially important in this patient since he reports having a cough. 
There are a few options for preventive therapy for tuberculosis. Regimens of isoniazid for nine months either as daily or twice weekly ther-
apy or short course preventive therapy of rifampin or rifabutin plus pyrazinamide have been recommended by CDC for patients with HIV
infection. Studies have demonstrated that short course preventive therapy of two months of daily rifampin and pyrazinamide is as effective
in preventing tuberculosis disease in HIV infected persons as isoniazid preventive therapy. All persons receiving preventive therapy, even
those without a prior history of therapy and/or untoward effects, should receive at least a monthly clinical evaluation for medication side
effects. 
One option I would consider for this inmate would be a careful rechallenge with isoniazid with monitoring, especially during the first sever-
al days of therapy, of hepatic enzymes and symptoms. If given twice weekly, isoniazid must be given in a directly observed manner.
Preventive therapy with pyrazinamide and rifampin for two months is another option and may be preferable, especially if there is docu-
mentation of significant hepatoxicity with prior isoniazid treatment.
This patient' s antiretrovial therapy of 3TC and AZT is inadequate. Consideration should be given to starting him on a regimen of highly
active antiretroviral therapy (HAART) which usually contains a protease-inhibitor. There are significant drug interactions between
rifamycins, specifically rifampin, and the protease inhibitors and some non-nucleoside reverse transcriptase inhibitors. If I were to treat the
patient with short course preventive therapy, I would handle the antiretroviral regimen in one of two ways. Start of HAART could be delayed
for two months until the short course preventive therapy is completed. Alternatively, HAART could be started and a modified short course
regimen would be used with pyrazinamide and substitution of rifabutin for rifampin. Use of rifabutin is contraindicated with ritonavir, hard-
gel saquinavir and delavirdine and data on the use of rifabutin with soft-gel saquinavir, aprenavir, efavirenz and nevirapine is limited. When
rifabutin is used in combination with indinavir, the dose of indinavir should be increased to 1200 mg every eight hours and the dose of
rifabutin should be reduced to 150 mg daily. In this patient with a history of nonadherence to therapy, preventive therapy should be deliv-
ered in an observed manner. 
Reference:
1. CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recom-
mendations. MMWR 1998:47 (RR-20).
A 45 year old man has a positive PPD skin test (>10mm) on routine TB testing in prison. Upon admission to jail, he also tested pos-
itive and was started on INH. He was intermittently adherent despite DOPT, and after four weeks on treatment he reported that he devel-
oped nausea, vomiting and yellow skin on the medication. He was told "not to take it again" but was not started on different medication.
He is now transferred to your prison. He is HIV seropositive, has a CD4 T cell count of 250, a viral load of 65,000 and he's been on
combivir (AZT/3TC combination) without the addition of a third drug for the past year. He has a smoker's cough, but no fever and no
night sweats.
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888.448.4911
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973.972.3270
TB Infoline: 
800.4TB.DOCS
National HIV Telephone
Consultation Service: 
800.933.3413
CDC National AIDS Hotline 
(24 hours): 
800.342.AIDS
Francis J Curry National 
Tuberculosis Center
415.502.4600
WEBSITES:
AIDS Treatment Data Network
http://204.179.124.69/network
The Body: An AIDS 
Information Resource
http://www.thebody.com
The Corrections Connection
http://www.corrections.com
Immunet and AIDS Treatment news
http://www.aids.org
International Association of
Physicians in AIDS Care (IAPAC)
http://www.iapac.org 
JAMA (Journal of the American
Medical Association) HIV/AIDS
Information Center
http://www.ama-assn.org/special/hiv 
Johns Hopkins AIDS Service,
http://www.hopkins-AIDS.edu 
Medscape HIV/AIDS 
(formerly known as Clinical Care
Options for HIV)
http://hiv.medscape.com/Home/Topics
/AIDS/AIDS.html
TB WEBSITES:
Francis J Curry National 
Tuberculosis Center
http://www.nationaltbcenter.edu
Post-Exposure Prophylaxis
Network
http://epi-center.ucsf.edu/PEP/
pepnet.html
NJ Medical School 
National TB Center
http://www.undnj.edu/ntbc
Brown University 
TB/HIV Research Lab
http://www.brown.edu/Research/TB-
HIV_Lab/
CDC TB Report
http://www.cdc.gov/epo/mmwr/mmwr.
html
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Tuberculosis in United States' Correctional Facilities
Mark N. Lobato, MD
Medical Officer, Field Services Branch, 
Division of TB Elimination
NCHSTP, CDC
Tuberculosis (TB) is an important public health issue in cor-
rectional facilities (1).  In 1997, 729 TB cases were report-
ed from correctional facilities, representing almost 4% of
national cases reported to the Centers for Disease Control
and Prevention (CDC) (2). Multiple factors account for the
high rates of TB infection and disease found among the
incarcerated population, primarily risk factors of the indi-
vidual inmates themselves (5). Conditions associated with
TB, such as poverty, drug use and HIV infection, are more
common in the incarcerated population than in the general
population (3). However, overcrowding in correctional facil-
ities is an independent risk factor for the acquisition of TB
infection by inmates (6). Despite widespread efforts to
reduce transmission within correctional facilities, TB out-
breaks within correctional facilities continue (4).
The CDC's publication in 1996 of Recommendations for
the Prevention and Control of Tuberculosis in Correctional
Facilities standardized measures to control TB in correc-
tional facilities.  Correctional facilities have the responsibil-
ity to assure that TB transmission does not occur in the
facility by mandating screening of inmates and staff (7).
When active disease is detected or suspected, potentially
infectious persons should be isolated in a negative pres-
sure room and administered adequate treatment (8).  If
transmission does occur, the facility should have a
response plan in place to curtail ongoing transmission that
may threaten staff, inmates and the community at large (9).
Assessment of TB screening and prevention efforts is an
integral component of TB control in correctional facilities
(6).
Correctional facilities are important arenas for public health
testing, treatment and prevention of TB, HIV and STDs.
Another critical challenge for TB control and prevention in
correctional facilities is to ensure that inmates who are
receiving treatment for TB disease or infection have ade-
quate discharge planning to improve continuity of care
(10).  Because almost all inmates will eventually return to
the community, interventions to prevent the spread of TB in
correctional facilities can make an important contribution to
the elimination of tuberculosis.
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Table: TB infection among inmates, 1997
% positive skin test State and Federal Prison Systems     City and County Jail Systems
n systems % cases n systems % cases
< 5% 21 41   6,515 12 29   6,131
5-9.9%   3   6   7,200 11 27   8,162
10-20%   1   2   1,283   5 12 16,165
No report 26 51      -- 13 32 --
Total 51 100 14,998 41 100 30,458
Source: NIJ/CDC 1997 survey: Tuberculosis in correctional facilities
Table: Prevalence of TB infection among inmates, 1997
Most systems reported a low prevalence of TB infection among inmates (21 of 51 state systems for a total of 6,515 cases).  A few
systems reported extremely high TB infection prevalence rates (one state or federal system and five city or county jails) accounting for
more than a third of the total number of cases.
Source: NIJ/CDC 1997 survey: Tuberculosis in correctional facilities
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News Flash from the 6th Conference on
Retroviruses and Opportunistic
Infections, January 31 to February 5,
1999.  To see these abstracts in full, see
the following website:
http://www.retroconference.org/99
A study conducted by Jody Rich, M.D.,
of the Brown University AIDS Program,
and a team including Anne Spaulding,
M.D., Medical Director of the Adult
Correctional Institution of Rhode Island,
found that HBV and HCV prevalence
rates are higher than HIV prevalence
rates among Rhode Island women
inmates.  HIV seroconversion was sig-
nificantly correlated with intravenous
drug use.  Rich et al. concluded that the
prison population represents an oppor-
tunity for the treatment and prevention
of blood-borne infections (Abstract No.
478).
A team of researchers from the Brown
University AIDS Program and the
Harvard Medical School, led by Ken
Mayer, M.D., and including Susan Cu-
Uvin, M.D., and Timothy Flanigan, M.D.,
found that treatment of various causes
of vaginitis (including bacterial vagi-
nosis, trichomoniasis and herpes sim-
plex virus) lowered viral load in the vagi-
nal secretions of 22 women.  Vaginitis
treatment may decrease CV in HIV
RNA, but effects of treatment on genital
WBC and cytokines are highly variable,
r flecting the complex micro-environ-
ment of the genital tract (Abstract No.
467).
An additional study led by Susan Cu-
Uvin and including the previously men-
tioned researchers found a significant
c rrelation between the detection of
HIV-1 RNA in the genital tract and both
Peripheral Viral Load (PVL) and CD4
cell count.  Women on HAART were
more likely to have Cervical Viral Load
(CVL) HIV-1 RNA at <400 copies/ml.
Women on any retroviral therapy were
more likely to have CVL HIV-1 RNA
at<400 copies per ml.
Frederick Altice, M.D. et al of the Yale
University AIDS Program presented a
study showing that Nevirapine, a potent
inducer of the P450 enzyme system,
may induce metabolism of methadone
and clinically precipitate opiate with-
drawal in patients receiving both med-
ications.  These results have important
implications for HIV therapeutics in opi-
ate-addicted persons and emphasize
the need to perform drug interaction
studies in this population (Abstract No.
372).
Next month's issue will focus on a more
detailed discussion of the The 6th
Conference on Retroviruses and
Opportunistic Infections.
News Flash 
HEPPigram
A feature of HEPPNews providing concise solutions to correctional HIV-related problems
Routine Office Visit TB Isolation Guidelines*
Case PPD
status
HIV
status
Symptoms Chest X-
ray
Procedure
A + - no normal
- no isolation needed
- evaluate whether appropriate for TB Px
B + - cough/fever normal
- evaluate for non-TB causes of fever
- rule out HIV (which may obscure x-ray findings)
 -re-evaluate need for isolation and further evaluation
    if in a high risk group for HIV or HIV seropositive
    (see row D)
C + - cough/fever abnormal - evaluate for non-TB causes of fever
- consider isolation while undergoing evaluation if no
other obvious cause of illness
- send sputum, urine, blood for AFBx3 and AFB culture
- reasons to isolate:
    if clinical suspicion of TB
    if known TB contact
    if known to be previously "partially treated" for TB
    if cough and fever is accompanied by other TB Sx
D + + no normal - no isolation needed
- strongly consider TB prophylaxis
E + + cough/fever normal - isolate (unless other causes of cough/fever are obvious):
this is an important “clinical judgment call”. Remember to
“Think TB!”
- send specimens for AFBx3 and AFB culture
- reasons to strongly consider isolation:
    if clinical suspicion of TB
    if recentTB contact
    if known to be previously "partially treated" for TB
    if cough and fever is accompanied by other TB Sx
F + + cough/fever abnormal** - isolate
- evaluate for TB among other possible causes for this
constellation of findings
- send sputum, urine, blood for AFBx3 and AFB culture
- consult TB treatment expert
*This chart provides general guidelines for isolation procedures for TB control in prisons.  The details, however, should be considered
on a case by case basis. 
**Classically, TB would present with apical infiltrates.  However, TB in the HIV infected individual can present in middle/lower lobe
infiltrates OR nodular infiltrates; OR any location cavity, etc.
Routine Office Visit TB Isolation Guidelines*
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FAX HEPP NEWS BACK AT 800.671.1754 FOR ANY OF THE FOLLOWING: (please print clearly or type)
____  Yes, I would like to add/update/correct (circle one) my contact information for my complimentary subscription of HEPPNews fax newsletter.
____  Yes, I would like to sign up the following colleague to receive a complimentary subscription of HEPPNews fax newsletter.
____  Yes, I would like to order the following back issues (please include volume/HIVInt rnet Resources).
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TITLE:______________________________________________________________________________________________
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ADDRESS:__________________________________________________________________________________________
FAX: ____________________________________________________ PHONE: ________________________________
SIGNATURE: ______________________________________________ DATE: __________________________________
Improving the Management of HIV Disease
March 24, 1999  New York, NY
April 21, 1999  Chicago, IL
May 8, 1999  Cleveland, OH
Reviews the most recent developments in the field of HIV disease patho-
genesis and antiretroviral management.  Expert faculty will speak on
timely and clinically relevant issues in the management of HIV disease.
Sponsored by: International AIDS Society-USA (IASUSA)
Contact:IASUSA
tel:  415.561.6725  
fax: 415. 561.6740
e-mail:  info@iasusa.org  
website: www.iasusa.org
11th National HIV/AIDS Update Conference: 
Partnering Science and Practice 
March 23-26, 1999
Sponsored by:AmFar (www.nauc.org)
Bill Graham Civic Auditorium
San Francisco, CA
Contact: KREBS Convention Management Services
tel: 415.920.7000  
fax: 415.920.7001
e-mail: krebsconv@aol.com
website: www.citysearch.com/sfo/krebs
1999 Community Planning Leadership 
Summit for HIV Prevention
March 24-27, 1999
Sponsored by:AED, CDC, NASTAD, NMAC
Pittsburgh Hilton & Towers, Pittsburgh PA
Contact:Harry Williams at NMAC
tel: 202.483.6622  
fax: 202.483.1127
Management of HIV/AIDS in the Correctional Setting:
Neurological Manifestations of HIV
May 11, 1999 12:30-3:30 p.m. EST
This live, interactive satellite videoconference series addresses clinical
issues in the management of HIV infected inmates.  No registration
fee.  CME credit offered.
Sponsored by: the Division of HIV Medicine at Albany Medical Center
in cooperation with the NYS Department of Correctional Services, the
NY/Virginia Islands AIDS Education and Training Centers, and the
NYS Centers for STD/HIV Prevention Training.  
Contact:Carol Kiner 
tel: 518.262.4674  
e-mail: kinerc@mail.amc.edu
AIDS and Tuberculosis:  International Conference in Pulmonary
and Critical Care Medicine
April 23-28, 1999
This yearly conference has become the premier, international forum for
physicians and scientists who work in pulmonary and 
critical care medicine. 
Sponsored by:  The American Thoracic Society
Contact:The American Thoracic Society
tel:  212.315.8700 
fax: 212.315.6498
website: http://www.thoracic.org/ic99/welcome.html
Ryan White Title III HIV Planning Grant Program 
Pre-Application Workshop
March 24, 1999, Jackson, MS
April 7, Cleveland, OH
April 9, Memphis, TN
April 12, Los Angeles, CA
April 14, Houston, TX
April 16, Denver, Co
The Ryan White Title III HIV Planning Grant Program provides up to
$50,000 for one year of funding, with the possibility of second-year
transitional grant, to support communities and health care service enti-
ties in their efforts to plan the establishment of HIV primary health care
services, including identifying needed components of care and forming
linkages with providers in the community.  This grant program supports
activites of the planning process and does not fund any service provi-
sion of patient care.
Sponsored by:  U.S. Department of Health and Human Services,
HRSA
Contact:PSA Conference Department, attention of Jason Linkins
tel: 703.852.2927
fax: 703.852.2901
website:  http://www.psava.com
HIV Care: The Next Decade
April 22, 1999, 8:30-2:30
Topics to be covered include substance abuse, salvage therapy and
metabolic complications, clinical and community-based HIV research,
new antiretroviral therapy approaches and antiretroviral treatment
updates.
Sponsored by:People With AIDS Coalition of New York, The NY
Academy of Medicine, Information Outreach, Bristol Meyers-Squibb,
Dupont, Upjohn and Roche Pharmaceuticals
Contact:People With AIDS Coalition of New York
tel: 800.828.3280
fax: 212.647.1419
S a v e  T h e  D a t e s
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through May
15, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. Which of the following HIV medications is most likely to
interact with rifampin:
a) Zidovudine (AZT, ZDV, Retrovir)
b) Saquinavir (SQV-HGC, Fortovase)
c) Stavudine (D4T, Verit)
d) Lamivudine (3TC, Epivir)
e) none of the above
2. An HIV-infected patient on a regimen of Zidovudine +
Didanosine + Nevirapine is found to have active TB. Which
of the following is an appropriate treatment option?
a) interruption of HIV regimen in order to begin TB 
treatment
b) delay of TB treatment in order to initiate another 
HIV regimen 
c) concomitant treatment of TB and HIV with a 
Rifampin-based combination TB treatment regimen 
d) concomitant treatment of TB and HIV with a 
Rifabutin-based combination TB treatment regimen
e) all of the above
3. In the setting of HIV infection, the continuation phase of
rifampin-based treatment of TB disease involves Directly
Observed Therapy with:
a) daily doses of Rifampin and Isoniazid for 18 weeks 
b) 2x/week doses of RIF and INH for 18 weeks
c) 3x/week doses of RIF, INH, Pyrazinamide, and 
Ethambutol for 18 weeks
d) 3x/week doses of RIF, INH, PZA and Streptomycin 
for 18 weeks
e) any of the above
4. Which of the following is not an individual risk factor
associated with TB among incarcerated populations?
a) overcrowding in correctional facilities
b) drug use
c) poverty
d) HIV infection
e) none of the above
5. Depending on the patient's stage of HIV infection, start
of HAART therapy in an untreated TB/HIV co-infected
patient can be delayed for 2 months until a short course of
TB preventive therapy has been completed. 
TRUE or FALSE 
BROWN UNIVERSITY SCHOOL OF MEDICINE • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME)t  sponsor contin-
uing medical education activities for physicians.  This activity has been planned and implemented in accordance with the Essentials and Standards
of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommenda-
tions and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the
Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
case study 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
save the date 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
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